久久无码人妻一区二区三区午夜_久久久久精品久久久久影院蜜桃_亚洲综合欧美色五月俺也去_交换娇妻呻吟声不停中文字幕

南京科佰生物科技有限公司

當前位置:南京科佰生物科技有限公司>>藥靶細胞株>>kinase激酶細胞株>> CBP73190BCR-ABL1 T315I/BaF3

BCR-ABL1 T315I/BaF3

參  考  價:面議
具體成交價以合同協議為準

產品型號CBP73190

品牌cobioer/科佰生物

廠商性質代理商

所在地南京市

更新時間:2022-04-28 11:41:51瀏覽次數:943次

聯系我時,請告知來自 化工儀器網
供貨周期 現貨 規格 T-25 Flask
貨號 CBP73190 應用領域 生物產業
主要用途 僅限科研使用
BCR-ABL1 [T315I]/BaF3,母細胞:BaF3,凍存條件:90% FBS+10% DMSO;
CBP73190
I. Introduction

Cell Line Name:

BCR-ABL1 [T315I]/BaF3

Host Cell:

Ba/F3

Stability:16 passages (in-house test, that not means the cell line will be instable beyond the passages we tested.)

Application:

Anti-proliferation assay and PD assay

Freeze Medium:

90% FBS+10% DMSO

Complete Culture Medium:

RPMI-1640+10%FBS

Mycoplasma Status:

Negative

 
II.Background

Presence of a BCR-ABL1 fusion gene is necessary for the pathogenesis of CML. In up to 95% of cases, a t(9;22) (q34;q11) translocation results in the BCR-ABL1 fusion gene (Faderl et al. 1999). This translocation results in the Philadephia chromosome. In rare CML cases lacking the traditional t(9;22) translocation, other translocations result in the creation of the BCR-ABL1 fusion gene, which sometimes involve multiple chromosomes.
ABL1 is a tyrosine kinase, and, in normal cells, it plays a role in cellular differentiation and regulation of the cell cycle. The BCR-ABL1 fusion gene creates a constitutively active tyrosine kinase, which leads to uncontrolled proliferation.
Imatinib is the first-generation ABL tyrosine kinase inhibitor, and it was approved by the FDA in 2001; label indications for CML include use in newly diagnosed adult and pediatric patients and in patients after failure of interferon-alpha therapy. While treatment responses to imatinib are often dramatic and lasting, 30–40% of patients will eventually need further treatment (Santos et al. 2011). In many but not all cases, this is due to the acquisition of point mutations in the tyrosine kinase domain of the BCR-ABL1 fusion gene, which renders the protein insensitive to the inhibitory effect of imatinib. This type of disease progression led to the development of second-line TKIs: dasatinib, nilotinib, and bosutinib. Dasatinib and bosutinib have the additional advantage of being inhibitors of SRC.
The second-generation TKIs, dasatinib, nilotinib, and bosutinib, are more potent than imatinib, and they were developed to treat cases of CML resistant to imatinib. Dasatinib and nilotinib are approved for use in CML in newly diagnosed adults, while dasatinib, nilotinib, and bosutinib are approved for use in adults with resistance or intolerance to prior therapy that included imatinib (FDA 2012). Soverini et al. (2011) made mutation-specific treatment decision recommendations that were adopted by NCCN (2012). Recommendations based on preclinical data are as follows: for T315I, HSCT or clinical trial; for V299L, T315A, and F317L/V/I/C, consider nilotinib rather than dasatinib; for Y253H, E255K/V, and F359V/C/I, consider dasatinib rather than nilotinib; and for all other mutations, consider high-dose imatinib, dasatinib, or nilotinib.
Ponatinib is a third-line TKI, developed specifically to address imatinib resistance due to the BCR-ABL1 T315I resistance mutation. Ponatinib is currently being investigated in phase III clinical trials.

 
III. Representative Data

1. WB of BCR-ABL1 [T315I]/BaF3


2. Sanger of BCR-ABL1 [T315I]/BaF3


Figure 2. BCR-ABL1 T315I/BaF3 T315I

Figure 3. BCR-ABL1 T315I/BaF3 Fusion

 

3. Anti-proliferation assay

Figure 4. CTG Proliferation Assay of BaF3 BCR-ABL1 T315I Cells.

CD74-ROS1 G2032R BaF3

CD74-ROS1 [G2032R] BaF3

CD74-ROS1 L2086F BaF3

CD74-ROS1 [L2086F] BaF3

KRAS G12D&Y96C BaF3

KRAS [G12D&Y96C] BaF3

會員登錄

×

請輸入賬號

請輸入密碼

=

請輸驗證碼

收藏該商鋪

X
該信息已收藏!
標簽:
保存成功

(空格分隔,最多3個,單個標簽最多10個字符)

常用:

提示

X
您的留言已提交成功!我們將在第一時間回復您~

以上信息由企業自行提供,信息內容的真實性、準確性和合法性由相關企業負責,化工儀器網對此不承擔任何保證責任。

溫馨提示:為規避購買風險,建議您在購買產品前務必確認供應商資質及產品質量。

撥打電話
在線留言
主站蜘蛛池模板: 崇阳县| 安乡县| 柏乡县| 喜德县| 来宾市| 集安市| 九台市| 张家川| 辽阳县| 安塞县| 普陀区| 商南县| 兴文县| 汽车| 昌都县| 天峻县| 蓝山县| 虞城县| 唐山市| 东丽区| 沿河| 韶山市| 日土县| 林周县| 元阳县| 阆中市| 富宁县| 河西区| 商丘市| 苏州市| 湘潭市| 甘泉县| 聂荣县| 电白县| 博湖县| 栾川县| 金堂县| 弥勒县| 金阳县| 眉山市| 通州区|